📊 ORIC Key Takeaways
Is Oric Pharmaceuticals, Inc. (ORIC) a Good Investment?
Oric is a clinical-stage pharmaceutical company with no revenue, burning $111.7M annually with only ~4-5 months of cash runway at current rates. While the balance sheet shows $384.4M in equity and minimal debt (0.03x D/E), the lack of product revenue, persistent operating losses of -$143M, and imminent need for capital raise present significant downside risk from shareholder dilution without visible path to profitability.
Why Buy Oric Pharmaceuticals, Inc. Stock? ORIC Key Strengths
- Minimal leverage with debt-to-equity of 0.03x and only $10.5M long-term debt
- Strong equity base of $384.4M providing financial cushion for operations
- Excellent liquidity position with 14.13x current ratio and $45.7M cash
- Improving EPS trajectory (+19.7% YoY) suggesting better operational efficiency
ORIC Stock Risks: Oric Pharmaceuticals, Inc. Investment Risks
- Critical cash runway of 4-5 months at current $111.7M annual burn rate
- Complete absence of revenue generation with no approved commercial products
- Massive operating losses of -$143.0M and net losses of -$129.5M indicate unsustainable operations
- Negative returns on equity (-33.7%) and assets (-31.7%) reflect value destruction
- Imminent capital raise likely needed, creating significant dilution risk for existing shareholders
Key Metrics to Watch
- Cash balance and runway months; timeline to next capital raise
- Clinical trial progress and FDA milestone achievement dates
- Monthly cash burn rate trend and operating expense management
- Pipeline advancement and probability of regulatory approval events
Oric Pharmaceuticals, Inc. (ORIC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.13x current ratio provides a solid financial cushion.
ORIC Profit Margin, ROE & Profitability Analysis
ORIC vs Healthcare Sector: How Oric Pharmaceuticals, Inc. Compares
How Oric Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oric Pharmaceuticals, Inc. Stock Overvalued? ORIC Valuation Analysis 2026
Based on fundamental analysis, Oric Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oric Pharmaceuticals, Inc. Balance Sheet: ORIC Debt, Cash & Liquidity
ORIC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oric Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.83 indicates the company is currently unprofitable.
ORIC Revenue Growth, EPS Growth & YoY Performance
Oric Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ORIC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oric Pharmaceuticals, Inc. (CIK: 0001796280)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ORIC
What is the AI rating for ORIC?
Oric Pharmaceuticals, Inc. (ORIC) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ORIC's key strengths?
Claude: Minimal leverage with debt-to-equity of 0.03x and only $10.5M long-term debt. Strong equity base of $384.4M providing financial cushion for operations.
What are the risks of investing in ORIC?
Claude: Critical cash runway of 4-5 months at current $111.7M annual burn rate. Complete absence of revenue generation with no approved commercial products.
What is ORIC's revenue and growth?
Oric Pharmaceuticals, Inc. reported revenue of N/A.
Does ORIC pay dividends?
Oric Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ORIC SEC filings?
Official SEC filings for Oric Pharmaceuticals, Inc. (CIK: 0001796280) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ORIC's EPS?
Oric Pharmaceuticals, Inc. has a diluted EPS of $-1.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ORIC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Oric Pharmaceuticals, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ORIC stock overvalued or undervalued?
Valuation metrics for ORIC: ROE of -33.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ORIC stock in 2026?
Our dual AI analysis gives Oric Pharmaceuticals, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ORIC's free cash flow?
Oric Pharmaceuticals, Inc.'s operating cash flow is $-111.0M, with capital expenditures of $712.0K.
How does ORIC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -33.7% (avg: 15%), current ratio 14.13 (avg: 2).